A Phase 4 interventional study of Lansoprazole (Lanton) and Omeprezole (Losec) in Helicobacter Pylori Infection, sponsored by Meridian Bioscience, Inc.. Completed at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-20.
Sponsored by Meridian Bioscience, Inc. (part of SD Biosensor) · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Approximately 200 patients with suspected H.pylori will be tested with a 13C-Urea Breath Test (UBT) to ascertain H.pylori positive. 100 H.Pylori positive patients will tested before and after prescribed with one of the four selected Proton Pump Inhibitors (PPIs); 25 patients in each arm. This will provide information on the influence of PPIs on the UBT (Urea Breath Test). The aim of the trial is to observe the effect of different PPIs on the breath test and choose the optimal protocol of when to stop PPI. The hypothesis is that there will be a minimal effect on the UBT while using selected PPIs.
Adult subjects with suspected H pylori infection will be recruited and will undergo a 13C -Urea breath test (including citrica) with the BreathID test device. Those were found positive will undergo selected PPI treatment for 14 days and after 24 or 72 hours from the completion of the two weeks, will undergo a second breath test. Those found to be negative (false negative), will undergo additional breath tests.
Meridian Bioscience, Inc. is the lead sponsor of 27 studies on the registry; none are open to participants now.
First submitted before Meridian Bioscience, Inc. became part of SD Biosensor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with H.pylori infection will take one tablet a day of 20 mg Lansoprazole for 14 days orally in the morning
Drug: Lansoprazole (Lanton)
Patients with H.pylori infection will take one tablet of 30 mg a day of Omeprazole for 14 days orally in the morning
Drug: Omeprezole (Losec)
Patients with H.pylori infection will take one tablet a day of 40 mg of Pantoprazole for 14 days orally in the morning
Drug: Pantoprazole(Controloc)
Patients with H.pylori infection will take one tablet a day of 20 mg Esomeprazole for 14 days orally on the morning
Drug: Esomeprazole (Nexium)
Oral administration of Lanzoprazole for 14 days in 25 patients with H.pylori infection
Also known as: Lanton
Oral administration of Omeprazole for 14 days in 25 patients with H.pylori infection
Also known as: Losec
Oral administration of Pantoprazole for 14 days in 25 patients with H.pylori infection
Also known as: Controloc
Oral administration of Esomeprazole for 14 days in 25 patients with H.pylori infection
Also known as: Nexium
Urea Breath Test Result (DOB > 5 is Positive)After Different Time Periods From When PPI (Proton Pump Inhibitor) Was Stopped.
Negative value is defined as delta over baseline (DOB) less than 5. The subjects who were positive (DOB\>=5) for H.Pylori and after PPI for 10 days repeated a breath with a negative (DOB\<5) were considered false negatives. The breath test has been cleared by the FDA in a 510(k) and has \> 96% accuracy.
Time frame: 17 days
Two out-patient clinics in hospitals will enroll subjects
| Milestone | Lansoprazole (Lanton) | Omeprazole( Losec) | Pantoprazole (Controloc) | Esomeprazole (Nexium) |
|---|---|---|---|---|
| Started | 29 | 62 | 19 | 13 |
| Completed | 29 | 62 | 19 | 13 |
| Not completed | 0 | 0 | 0 | 0 |
Negative value is defined as delta over baseline (DOB) less than 5. The subjects who were positive (DOB\>=5) for H.Pylori and after PPI for 10 days repeated a breath with a negative (DOB\<5) were considered false negatives. The breath test has been cleared by the FDA in a 510(k) and has \> 96% accuracy.
| participants | Lansoprazole (Lanton) | Omeprazole( Losec) | Pantoprazole (Controloc) | Esomeprazole (Nexium) |
|---|---|---|---|---|
| False negatives (DOB<5) after 3 days of no PPI | 1 | 3 | 1 | 0 |
| False negatives (DOB<5) after 1 day of no PPI | 2 | 4 | 2 | 1 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lansoprazole (Lanton) | — | 0/29 (0%) | 0/29 (0%) |
| Omeprazole( Losec) | — | 0/62 (0%) | 0/62 (0%) |
| Pantoprazole (Controloc) | — | 0/19 (0%) | 0/19 (0%) |
| Esomeprazole (Nexium) | — | 0/13 (0%) | 0/13 (0%) |
| Age, Categorical(Participants) | Lansoprazole (Lanton) | Omeprazole( Losec) | Pantoprazole (Controloc) | Esomeprazole (Nexium) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 26 | 55 | 17 | 9 | 107 |
| >=65 years | 3 | 7 | 2 | 4 | 16 |
| Age, Continuous(years) | Lansoprazole (Lanton) | Omeprazole( Losec) | Pantoprazole (Controloc) | Esomeprazole (Nexium) | Total |
|---|---|---|---|---|---|
| Mean | 52.86 ± 14.67 | 52.48 ± 13.35 | 51.84 ± 12.78 | 55.38 ± 14.84 | 52.46 ± 14.01 |
| Sex: Female, Male(Participants) | Lansoprazole (Lanton) | Omeprazole( Losec) | Pantoprazole (Controloc) | Esomeprazole (Nexium) | Total |
|---|---|---|---|---|---|
| Female | 20 | 40 | 15 | 7 | 82 |
| Male | 9 | 22 | 4 | 6 | 41 |
| Region of Enrollment(participants) | Lansoprazole (Lanton) | Omeprazole( Losec) | Pantoprazole (Controloc) | Esomeprazole (Nexium) | Total |
|---|---|---|---|---|---|
| Israel | 29 | 62 | 19 | 13 | 123 |
| H. Pyori Positive(particpants) | Lansoprazole (Lanton) | Omeprazole( Losec) | Pantoprazole (Controloc) | Esomeprazole (Nexium) | Total |
|---|---|---|---|---|---|
| Number | 29 | 62 | 19 | 13 | 123 |
The record gives a start of Nov 2008, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lansoprazole · Omeprazole · Esomeprazole